XOMA

XOMA Royalty Corp

40.17

Jul 13 • 03:59PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: LGND BMRN INCY RYTM VRTX FNV OR RGLD WPM NBIX

| Held by: VTI VXF VTWO VHT VTWG VTWV VTHR

Index	-
Market Cap	710.16M
Enterprise Value	760.00M
Income	19.95M
Sales	48.55M
Book/sh	7.79
Cash/sh	5.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	14
IPO	Jun 06, 1986

P/E	25.57
Forward P/E	-
PEG	-
P/S	14.63
P/B	5.15
P/C	7.48
P/FCF	107.11
EV/EBITDA	91.68
EV/Sales	15.65
Quick Ratio	3.59
Current Ratio	3.59
Debt/Eq	1.10
LT Debt/Eq	0.96
Option/Short	Yes / No

EPS (ttm)	1.57
EPS next Y	-0.05
EPS next Q	0.18
EPS this Y	-46.22%
EPS next Y	-106.10%
EPS next 5Y	-
EPS past 3/5Y	- 13.20%
Sales past 3/5Y	105.30% 12.16%
EPS Y/Y TTM	249.73%
Sales Y/Y TTM	13.16%
EPS Q/Q	207.83%
Sales Q/Q	-22.59%
Earnings	Apr 30
EPS/Sales Surpr.	30.51% 0.26%

Insider Own	2.33%
Insider Trans	0.00%
Inst Own	84.96%
Inst Trans	5.33%
ROA	10.55%
ROE	25.88%
ROIC	11.55%
Gross Margin	93.16%
Oper. Margin	10.25%
Profit Margin	41.08%
SMA20	-5.68%
SMA50	-4.49%
SMA200	19.20%
Trades

Shs Outstand	17.68M
Shs Float	17.27M
Short Float	5.30%
Short Ratio	2.73
Short Interest	0.91M
52W High	45.22 -11.17%
52W Low	22.29 80.22%
Volatility	3.85% 1.79%
ATR (14)	0.91
RSI (14)	34.34
Beta	0.88
Rel Volume	0.00
Avg Volume	335.20K
Volume	0

Perf Week	-9.16%
Perf Month	-3.85%
Perf Quarter	1.41%
Perf Half Y	36.82%
Perf YTD	51.07%
Perf Year	48.01%
Perf 3Y	135.74%
Perf 5Y	22.32%
Perf 10Y	292.29%
Recom	3.00
Target Price	39.00
Prev Close	40.17
Price	40.17
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	The Benchmark Company	Buy	$35
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6

Show Previous Ratings

Jul-14-26 09:00AM	XOMA Royalty Announces Closing of Its Acquisition by Ligand (GlobeNewswire)
Jun-12-26 04:05PM	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date (GlobeNewswire)
11:47AM	Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-14-26 05:25PM	Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-08-26 05:57PM	Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? (PR Newswire)
02:55PM	Loading…
May-04-26 02:55PM	Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-27-26 11:24AM	Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? (PR Newswire) +10.74%
10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Mar-18-26 04:30PM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +5.16%
06:00AM	XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Mar-12-26 06:30AM	XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026 (GlobeNewswire)
Feb-18-26 04:30PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-09-26 09:53AM	XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. (GlobeNewswire)
07:30AM	Loading…
Jan-12-26 07:30AM	XOMA Royalty Announces CFO Transition (GlobeNewswire) -10.25%
Jan-05-26 08:48AM	Implied Volatility Surging for XOMA Royalty Stock Options (Zacks)
Dec-30-25 07:30AM	XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab (GlobeNewswire)
Dec-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-12-25 12:28PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily)
09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-11-25 06:41PM	Xoma Crumbles And Partner Rezolute Collapses On Failed Insulin Disease Drug (Investor's Business Daily) -22.76%
Dec-05-25 09:00AM	XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc (GlobeNewswire)
Nov-21-25 07:45AM	XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Nov-12-25 08:45AM	XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Nov-04-25 10:15AM	Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-28-25 08:40AM	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates (Zacks)
Oct-20-25 09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
11:45AM	Loading…
Oct-17-25 11:45AM	XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement (GlobeNewswire)
Oct-02-25 04:43PM	XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. (GlobeNewswire)
Sep-24-25 06:00AM	ESSA Pharma Inc. Amends Agreement with XenoTherapeutics (PR Newswire)
Sep-23-25 02:00AM	Why Xoma, a drug royalty firm, is hunting biotech zombies (BioPharma Dive)
Sep-22-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-19-25 09:55AM	Does XOMA Royalty (XOMA) Have the Potential to Rally 85.34% as Wall Street Analysts Expect? (Zacks)
Sep-17-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. (GlobeNewswire)
Sep-03-25 09:55AM	Wall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should Know (Zacks)
07:30AM	XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-01-25 09:55AM	Here's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-20-25 12:52PM	Xoma, a drug royalty specialist, buys another zombie biotech (BioPharma Dive)
08:49AM	Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share (GlobeNewswire)
Aug-18-25 09:55AM	How Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15% (Zacks)
Aug-13-25 04:55PM	LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +8.54%
08:55AM	XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:51AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
Aug-11-25 09:00AM	XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics (GlobeNewswire)
Aug-07-25 05:25PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-06-25 09:10AM	Novavax (NVAX) Q2 Earnings and Revenues Top Estimates (Zacks) -7.10%
Aug-04-25 08:15AM	Xoma strikes deals to buy struggling biotechs HilleVax, Lava (BioPharma Dive) +10.01%
07:30AM	XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right (GlobeNewswire)
07:00AM	HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right (GlobeNewswire)
Jul-14-25 08:00AM	ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction (PR Newswire)
Jul-10-25 04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jun-27-25 07:30AM	Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jun-24-25 10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks) +5.23%
Jun-18-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
May-27-25 08:01AM	XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million (GlobeNewswire)
May-13-25 08:50AM	XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates (Zacks) +10.89%
07:48AM	XOMA Royalty: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements (GlobeNewswire)
May-07-25 07:30AM	XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference (GlobeNewswire) +6.25%
Apr-22-25 04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-14-25 07:30AM	XOMA Royalty Completes Sale of Kinnate Pipeline Assets (GlobeNewswire)
Apr-09-25 09:45AM	XOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey) +7.62%
Apr-08-25 07:15AM	BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 (ACCESSWIRE)
12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-02-25 07:30AM	XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference (GlobeNewswire)
Mar-20-25 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-17-25 04:30PM	XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements (GlobeNewswire)
Feb-24-25 04:05PM	XOMA Royalty to Present at Investor Conferences in March (GlobeNewswire)
Feb-04-25 07:30AM	XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-19-24 07:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-02-24 07:30AM	XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio (GlobeNewswire)
Nov-11-24 12:00PM	What Makes XOMA Royalty (XOMA) a New Buy Stock (Zacks)
Nov-07-24 09:00AM	XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.96%
07:52AM	XOMA Royalty: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Oct-22-24 08:00AM	XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience (GlobeNewswire)
08:00AM	Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash (Business Wire)
Sep-23-24 06:30AM	Zevra's MIPLYFFA (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
05:30AM	XOMA Royalty Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-04-24 07:30AM	XOMA Royalty to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 08:45AM	XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.40%
07:39AM	XOMA Royalty: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
Jul-18-24 04:08AM	Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-21-24 07:54AM	Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock? (Zacks) -5.23%
Jun-20-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +15.64%
Jun-12-24 07:30AM	XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher (GlobeNewswire)
06:00AM	3 Crazy Good Stocks to Buy With $500 Right Now (InvestorPlace)
May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

CEO & DirectorMr. Owen P. Hughes Jr.

Chief Investment OfficerMr. Bradley Sitko

Chief Financial OfficerMr. Jeffrey Trigilio

Head of Investor RelationsJuliane Snowden

Chief Legal Officer & Corporate SecretaryMs. Maricel Perea Montano

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Trigilio Jeffrey	Chief Financial Officer	Apr 20 '26	Option Exercise	0.00	11,538	0	103,906	Apr 22 04:30 PM
Montano Maricel Perea	Chief Legal Officer	Apr 20 '26	Option Exercise	0.00	3,370	0	41,793	Apr 22 04:30 PM
Hughes Owen	Chief Executive Officer	Apr 20 '26	Option Exercise	0.00	10,568	0	191,264	Apr 22 04:30 PM
Sitko Bradley	Chief Investment Officer	Apr 20 '26	Option Exercise	0.00	3,737	0	82,961	Apr 22 04:30 PM
Trigilio Jeffrey	Chief Financial Officer	Apr 13 '26	Option Exercise	0.00	4,000	0	94,000	Apr 15 06:13 PM
LIMBER JOSEPH M	Director	Mar 27 '26	Option Exercise	11.20	3,026	33,891	9,234	Mar 31 04:30 PM
WYSZOMIERSKI JACK L	Director	Mar 24 '26	Option Exercise	11.20	3,026	33,891	21,530	Mar 26 04:30 PM
Hughes Owen	Chief Executive Officer	Dec 04 '25	Buy	25.05	100,000	2,505,000	102,000	Dec 08 04:30 PM
Sitko Bradley	Chief Investment Officer	Sep 19 '25	Option Exercise	0.00	6,712	0	19,822	Sep 23 05:32 PM
Hughes Owen	Chief Executive Officer	Sep 19 '25	Option Exercise	0.00	35,567	0	98,268	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 19 '25	Option Exercise	0.00	11,846	0	34,409	Sep 23 05:32 PM
BURNS THOMAS M.	SVP, Finance & CFO	Sep 22 '25	Sale	35.99	4,330	155,820	30,079	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 19 '25	Option Exercise	0.00	3,033	0	12,134	Sep 23 05:32 PM
Montano Maricel Perea	Chief Legal Officer	Sep 10 '25	Option Exercise	0.00	9,101	0	9,101	Sep 12 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XOMA

XOMA Royalty Corp

Upgrade your Finviz experience